These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
554 related articles for article (PubMed ID: 17145843)
41. Monoclonal antibody studies in B(non-T)-cell malignancies. Shimoyama M; Minato K; Tobinai K; Nagai M; Hirose M Jpn J Clin Oncol; 1983 Sep; 13(3):477-88. PubMed ID: 6417373 [TBL] [Abstract][Full Text] [Related]
42. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. Magro CM; Dyrsen ME J Cutan Pathol; 2008 Nov; 35(11):1040-9. PubMed ID: 18681860 [TBL] [Abstract][Full Text] [Related]
43. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Karlsson C; Hansson L; Celsing F; Lundin J Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854 [TBL] [Abstract][Full Text] [Related]
44. Alemtuzumab in T-cell malignancies. Dearden CE; Matutes E; Catovsky D Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489 [TBL] [Abstract][Full Text] [Related]
45. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Buggins AG; Mufti GJ; Salisbury J; Codd J; Westwood N; Arno M; Fishlock K; Pagliuca A; Devereux S Blood; 2002 Sep; 100(5):1715-20. PubMed ID: 12176892 [TBL] [Abstract][Full Text] [Related]
46. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014 [TBL] [Abstract][Full Text] [Related]
47. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Rowan W; Tite J; Topley P; Brett SJ Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507 [TBL] [Abstract][Full Text] [Related]
48. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Belov L; de la Vega O; dos Remedios CG; Mulligan SP; Christopherson RI Cancer Res; 2001 Jun; 61(11):4483-9. PubMed ID: 11389079 [TBL] [Abstract][Full Text] [Related]
50. The emerging role of alemtuzumab in chronic lymphocytic leukemia. Nabhan C Clin Lymphoma Myeloma; 2005 Sep; 6(2):115-21. PubMed ID: 16231849 [TBL] [Abstract][Full Text] [Related]
51. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression. Saito Y; Nakahata S; Yamakawa N; Kaneda K; Ichihara E; Suekane A; Morishita K Leukemia; 2011 Jun; 25(6):921-31. PubMed ID: 21394097 [TBL] [Abstract][Full Text] [Related]
52. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312 [TBL] [Abstract][Full Text] [Related]
53. Preferential expression of the mucosal homing receptor integrin alpha 4 beta 7 in gastrointestinal non-Hodgkin's lymphomas. Drillenburg P; van der Voort R; Koopman G; Dragosics B; van Krieken JH; Kluin P; Meenan J; Lazarovits AI; Radaszkiewicz T; Pals ST Am J Pathol; 1997 Mar; 150(3):919-27. PubMed ID: 9060830 [TBL] [Abstract][Full Text] [Related]
54. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407 [TBL] [Abstract][Full Text] [Related]
55. CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Chang ST; Lu CL; Chuang SS Leuk Lymphoma; 2007 Jan; 48(1):117-21. PubMed ID: 17325855 [TBL] [Abstract][Full Text] [Related]
57. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. Epstein AL; Marder RJ; Winter JN; Fox RI J Immunol; 1984 Aug; 133(2):1028-36. PubMed ID: 6376628 [TBL] [Abstract][Full Text] [Related]
58. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779 [TBL] [Abstract][Full Text] [Related]
60. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism. Taylor VC; Sims M; Brett S; Field MC Biochem J; 1997 Mar; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]